SKYE insider filing: 5AM-managed funds disclose August 2025 sales
Rhea-AI Filing Summary
Insider sales by a director/10% owner over two days. Andrew J. Schwab, reporting as a director and a 10% owner through affiliated 5AM entities, reported multiple open-market dispositions of Skye Bioscience (SKYE) common stock on 08/21/2025 and 08/22/2025. The filings show weighted-average sale prices in two ranges: $3.55–$3.69 for 08/21 and $3.30–$3.59 for 08/22. Reported individual dispositions total 58,642; 2,314; 163,979; and 6,470 shares across the two days, with ownership reported on various lines as indirect through 5AM Ventures II, 5AM Co-Investors II, and 5AM Ventures VII. The form is signed by Mr. Schwab on 08/22/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director sold a material block of shares across two days; transactions were disclosed with weighted-average prices.
The Form 4 discloses open-market sales totaling 231,405 shares across two trading days at weighted-average price ranges of $3.30–$3.69. Sales were executed by or through affiliated venture funds, and post-transaction beneficial ownership is reported indirectly for several fund vehicles. From an analyst perspective, the filing is a routine Section 16 disclosure showing insider liquidity rather than option exercise or derivative activity; the report provides prices and counts but does not state motivating factors. The filing is compliant and transparent about indirect ownership structures.
TL;DR: Multiple small block sales by a director/10% owner disclosed; ownership held indirectly via venture partnerships.
Governance review: the reporting person is identified as a director and 10% owner who holds shares indirectly through several 5AM-managed entities. The Form 4 includes explanatory footnotes clarifying general partner relationships and disclaimers of direct beneficial ownership. The disclosure meets Section 16 requirements and includes weighted-average price ranges and an offer to provide per-price breakdowns on request, which supports regulatory transparency. No derivative transactions or amendments are reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 163,979 | $3.42 | $561K |
| Sale | Common Stock | 6,470 | $3.42 | $22K |
| Sale | Common Stock | 58,642 | $3.57 | $209K |
| Sale | Common Stock | 2,314 | $3.57 | $8K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
